Charioteer Pharmaceutical
Charioteer Pharmaceutical, also known as Charioteer, is a prominent player in the pharmaceutical industry, headquartered in China with significant operations across Asia and beyond. Founded in 2005, the company has established itself as a leader in the development and manufacturing of innovative healthcare solutions, focusing on areas such as oncology, cardiology, and neurology. Charioteer Pharmaceutical is renowned for its unique portfolio of generic and proprietary medications, which are distinguished by their high quality and affordability. The company has achieved notable milestones, including several successful product launches and partnerships that have expanded its market reach. With a commitment to research and development, Charioteer continues to enhance its position in the global pharmaceutical landscape, striving to improve patient outcomes through accessible and effective treatments.
DitchCarbon Score
How does Charioteer Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Charioteer Pharmaceutical's score of 10 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Charioteer Pharmaceutical's reported carbon emissions
Charioteer Pharmaceuticals currently does not have publicly available carbon emissions data for recent years, as no specific figures have been reported. Additionally, there are no documented reduction targets or initiatives outlined in their climate commitments. This absence of data suggests that the company may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the pharmaceutical industry, companies are increasingly recognising the importance of addressing carbon emissions and setting ambitious climate targets. As such, Charioteer Pharmaceuticals may benefit from establishing clear reduction goals and engaging in industry-standard initiatives to enhance their sustainability profile.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Charioteer Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
